If the R&D was done in university labs at public expense one may argue that there was a case of negligent representation of the public financial interest. If the drug at that time was supposedly effective then its IP value should have been part of the puchase price. If not someone was asleep at the switch.

In any case the article should have clarified the commercial risk and financial circumstances.